1 NovoLog[®]

2 Insulin aspart (rDNA origin) Injection

- 3
- 4

5 **DESCRIPTION**

6 NovoLog[®] (insulin aspart [rDNA origin] injection) is a human insulin analog that is a rapid-

7 acting, parenteral blood glucose-lowering agent. NovoLog is homologous with regular human


8 insulin with the exception of a single substitution of the amino acid proline by aspartic acid in

9 position B28, and is produced by recombinant DNA technology utilizing *Saccharomyces*

10 *cerevisiae* (baker's yeast) as the production organism. Insulin aspart has the empirical formula

11 $C_{256}H_{381}N_{65}0_{79}S_6$ and a molecular weight of 5825.8.

12



13

14 Figure 1. Structural formula of insulin aspart.

15

16 NovoLog is a sterile, aqueous, clear, and colorless solution, that contains insulin aspart (B28

asp regular human insulin analog) 100 Units/mL, glycerin 16 mg/mL, phenol 1.50 mg/mL,

metacresol 1.72 mg/mL, zinc 19.6 μ g/mL, disodium hydrogen phosphate dihydrate 1.25

19 mg/mL, and sodium chloride 0.58 mg/mL. NovoLog has a pH of 7.2-7.6. Hydrochloric acid

20 10% and/or sodium hydroxide 10% may be added to adjust pH.

21

22 CLINICAL PHARMACOLOGY

23 Mechanism of Action

24 The primary activity of NovoLog is the regulation of glucose metabolism. Insulins, including

25 NovoLog, bind to the insulin receptors on muscle and fat cells and lower blood glucose by

26 facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose

- 27 from the liver.
- 28

29 In standard biological assays in mice and rabbits, one unit of NovoLog has the same glucose-

30 lowering effect as one unit of regular human insulin. In humans, the effect of NovoLog is

- more rapid in onset and of shorter duration, compared to regular human insulin, due to its
- faster absorption after subcutaneous injection (see Figure 2 and Figure 3).
- 33


34 **Pharmacokinetics**

- 35 The single substitution of the amino acid proline with aspartic acid at position B28 in
- 36 NovoLog reduces the molecule's tendency to form hexamers as observed with regular human
- 37 insulin. NovoLog is, therefore, more rapidly absorbed after subcutaneous injection compared
- 38 to regular human insulin.
- 39
- 40 Bioavailability and Absorption NovoLog has a faster absorption, a faster onset of action, and
- a shorter duration of action than regular human insulin after subcutaneous injection (see

42 Figure 2 and Figure 3). The relative bioavailability of NovoLog compared to regular human

43 insulin indicates that the two insulins are absorbed to a similar extent.

44



45 46

Figure 2. Serial mean serum free insulin concentration collected up to 6 hours following a
 single pre-meal dose of NovoLog (solid curve) or regular human insulin (hatched curve)

49 injected immediately before a meal in 22 patients with Type 1 diabetes.

50

In studies in healthy volunteers (total n=107) and patients with Type 1 diabetes (total n=40),

52 NovoLog consistently reached peak serum concentrations approximately twice as fast as

regular human insulin. The median time to maximum concentration in these trials was 40 to

54 50 minutes for NovoLog versus 80 to 120 minutes for regular human insulin. In a clinical trial

55 in patients with Type 1 diabetes, NovoLog and regular human insulin, both administered

subcutaneously at a dose of 0.15 U/kg body weight, reached mean maximum concentrations of

57 82.1 and 35.9 mU/L, respectively. Pharmacokinetic/pharmacodynamic characteristics of

insulin aspart have not been established in patients with Type 2 diabetes.

59 The intra-individual variability in time to maximum serum insulin concentration for healthy

60 male volunteers was significantly less for NovoLog than for regular human insulin. The

61 clinical significance of this observation has not been established.

62 In a clinical study in healthy non-obese subjects, the pharmacokinetic differences between

63 NovoLog and regular human insulin described above, were observed independent of the

64 injection site (abdomen, thigh, or upper arm). Differences in pharmacokinetics between

65 NovoLog® and regular human insulin are not associated with differences in overall glycemic

66 control.


68 Distribution and Elimination - NovoLog has a low binding to plasma proteins, 0-9%, similar

- 69 to regular human insulin. After subcutaneous administration in normal male volunteers
- 70 (n=24), NovoLog was more rapidly eliminated than regular human insulin with an average
- apparent half-life of 81 minutes compared to 141 minutes for regular human insulin.
- 72

73 Pharmacodynamics

Studies in normal volunteers and patients with diabetes demonstrated that NovoLog has amore rapid onset of action than regular human insulin.

- ⁷⁶ In a 6-hour study in patients with Type 1 diabetes (n=22), the maximum glucose-lowering
- effect of NovoLog occurred between 1 and 3 hours after subcutaneous injection (see Figure 3).
- 78 The duration of action for NovoLog is 3 to 5 hours compared to 5 to 8 hours for regular human
- ⁷⁹ insulin. The time course of action of insulin and insulin analogs such as NovoLog may vary
- 80 considerably in different individuals or within the same individual. The parameters of
- 81 NovoLog activity (time of onset, peak time and duration) as designated in Figure 3 should be
- considered only as general guidelines. The rate of insulin absorption and consequently the
- 83 onset of activity is known to be affected by the site of injection, exercise, and other variables
- 84 (see PRECAUTIONS, General). Differences in pharmacodynamics between NovoLog® and
- regular human insulin are not associated with differences in overall glycemic control.
- 86



87 88

Figure 3. Serial mean serum glucose collected up to 6 hours following a single pre-meal dose of NovoLog (solid curve) or regular human insulin (hatched curve) injected immediately

- before a meal in 22 patients with Type 1 diabetes.
- 92

93 Special Populations

- 94 *Children and Adolescents* The pharmacokinetic and pharmacodynamic properties of
- NovoLog and regular human insulin were evaluated in a single dose study in 18 children (6-12
- years, n=9) and adolescents (13-17 years [Tanner grade \geq 2], n=9) with Type 1 diabetes. The
- 97 relative differences in pharmacokinetics and pharmacodynamics in children and adolescents
- with Type 1 diabetes between NovoLog and regular human insulin were similar to those in
- healthy adult subjects and adults with Type 1 diabetes.

100
 101 *Geriatrics* - The effect of age on the pharmacokinetics and pharmacodynamics of NovoLog
 102 has not been studied.
 103

Gender - In healthy volunteers, no difference in insulin aspart levels was seen between men
 and women when body weight differences were taken into account. There was no significant
 difference in efficacy noted (as assessed by HbAlc) between genders in a trial in patients with
 Type 1 diabetes.

108

Obesity - In a study of 23 patients with type 1 diabetes and a wide range of body mass index
 (BMI, 22-39 kg/m²), the pharmacokinetic parameters, AUC and Cmax, of NovoLog® were
 generally unaffected by BMI. Clearance of NovoLog® was reduced by 28% in patients with
 BMI >32 compared to patients with BMI <23 when a single dose of 0.1 U/kg NovoLog® was
 administered. However, only 3 patients with BMI <23 were studied.

114

Ethnic Origin - The effect of ethnic origin on the pharmacokinetics of NovoLog has not beenstudied.

117

Renal Impairment - Some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. A single subcutaneous dose of NovoLog® was administered in a study of 18 patients with creatinine clearance values ranging from normal to <30 mL/min and not requiring hemodialysis. No apparent effect of creatinine clearance values on AUC and Cmax of NovoLog® was found. However, only 2 patients with severe renal impairment were studied (<30 mL/min). Careful glucose monitoring and dose adjustments of insulin, including NovoLog, may be necessary in patients with renal dysfunction (see

- 125 PRECAUTIONS, Renal Impairment).
- 126

Hepatic Impairment - Some studies with human insulin have shown increased circulating
levels of insulin in patients with liver failure. In an open-label, single-dose study of 24
patients with Child-Pugh Scores ranging from 0 (healthy volunteers) to 12 (severe hepatic
impairment), no correlation was found between the degree of hepatic failure and any

- NovoLog® pharmacokinetic parameter. Careful glucose monitoring and dose adjustments of
 insulin, including NovoLog, may be necessary in patients with hepatic dysfunction (see
- 132 Insum, including NovoLog, may be necessary in patien133 PRECAUTIONS, Hepatic Impairment).
- 134

135 *Pregnancy* - The effect of pregnancy on the pharmacokinetics and glucodynamics of

- 136 NovoLog has not been studied (see PRECAUTIONS, Pregnancy).
- 137

Smoking - The effect of smoking on the pharmacokinetics/pharmacodynamics of NovoLog hasnot been studied.

140

141 CLINICAL STUDIES

- 142 To evaluate the safety and efficacy of NovoLog in patients with Type 1 diabetes, two
- 143 six-month, open-label, active-control (NovoLog vs. Novolin[®] R) studies were conducted (see
- 144 Table 1). NovoLog was administered by subcutaneous injection immediately prior to meals

145 and regular human insulin was administered by subcutaneous injection 30 minutes before meals. NPH insulin was administered as the basal insulin in either single or divided daily 146 doses. Changes in HbA1c, the rates of hypoglycemia (as determined from the number of 147 events requiring intervention from a third party), and the incidence of ketosis were clinically 148 comparable for the two treatment regimens. The mean total daily doses of insulin were greater 149 (1-3 U/day) in the NovoLog-treated patients compared to patients who received regular human 150 insulin. This difference was primarily due to basal insulin requirements. To achieve 151 152 improved glycemic control, some patients required more than three doses of meal-related insulin and/or more than one dose of basal insulin (see Table 1). No serum glucose 153 measurements were obtained in these studies. 154

155

To evaluate the safety and efficacy of NovoLog in patients with Type 2 diabetes, one sixmonth, open-label, active-control (NovoLog vs. Novolin R) study was conducted (see Table

1). NovoLog was administered by subcutaneous injection immediately prior to meals and

regular human insulin was administered by subcutaneous injection 30 minutes before meals.

160 NPH insulin was administered as the basal insulin in either single or divided daily doses.

161 Changes in HbAlc and the rates of hypoglycemia (as determined from the number of events

requiring intervention from a third party) were clinically comparable for the two treatment

regimens. The mean total daily dose of insulin was greater (2 U/day) in the NovoLog-treated

patients compared to patients who received regular human insulin. This difference was
 primarily due to basal insulin requirements. To achieve improved glycemic control, some

patients required more than three doses of meal-related insulin and/or more than one dose of

167 basal insulin (see Table 1).

168

169 Table 1. Results of two six-month, active-control, open-label trials in patients with Type 1

diabetes (Studies A and B) and one six-month, active-control, open-label trial in patients with
 Type 2 diabetes (Study C).

172

Study	Treatment (n)	Mean HbA1c (%) Baseline Month		Hypoglycemia ¹ (events / month / patient)		% of Patients Using Various Numbers of Insulin Injections / Day ²			
				1 /	Rapid-acting			Basal	
			6		1 - 2	3	4 - 5	1	2
Α	NovoLog (n=694)	8.0	7.9	0.06	3	75	22	54	46
	Novolin R (n=346)	8.0	8.0	0.06	6	75	19	63	37
В	NovoLog (n=573)	7.9	7.8	0.08	4	90	6	94	6
	Novolin R (n=272)	8.0	7.9	0.06	4	91	4	93	7
С	NovoLog (n=90)	8.1	7.7	0.02	4	93	4	97	4
	Novolin R (n=86)	7.8	7.8	0.01	2	93	5	93	7

173

175

¹ Events requiring intervention from a third party during the last three months of treatment

² Percentages are rounded to the nearest whole number

176 To evaluate the use of NovoLog by subcutaneous infusion with an external pump, two open-

177 label, parallel design studies (6 weeks [n=29] and 16 weeks [n=118]) compared NovoLog

- versus Velosulin (buffered regular human insulin) in patients with Type 1 diabetes. Changes in
- 179 HbA1c and rates of hypoglycemia were comparable. Patients with Type 2 diabetes were also
- 180 studied in an open-label, parallel design trial (16 weeks [n=127]) using NovoLog by
- 181 subcutaneous infusion compared to pre-prandial injection (in conjunction with basal NPH
- injections). Reductions in HbA1c and rates of hypoglycemia were comparable. (See
- 183 INDICATIONS AND USAGE, WARNINGS, PRECAUTIONS, Mixing of Insulins,
- 184 Information for Patients, DOSAGE AND ADMINISTRATION, and RECOMMENDED
- 185 STORAGE.)
- 186

187 INDICATIONS AND USAGE

- 188 NovoLog is indicated for the treatment of adult patients with diabetes mellitus, for the control
- 189 of hyperglycemia. Because NovoLog has a more rapid onset and a shorter duration of activity 190 than human regular insulin, NovoLog given by injection should normally be used in regimens
- with an intermediate or long-acting insulin. NovoLog may also be infused subcutaneously by
- external insulin pumps. (See WARNINGS, PRECAUTIONS [especially Usage in Pumps],
- Information for Patients [especially For Patients Using Pumps], Mixing of Insulins, DOSAGE
- 193 Information for Patients [especially For Patients Using Pumps], Mixing of Insulins, DUSAC
- 194 AND ADMINISTRATION, RECOMMENDED STORAGE.)195

196 CONTRAINDICATIONS

- NovoLog is contraindicated during episodes of hypoglycemia and in patients hypersensitive to
 NovoLog or one of its excipients.
- 199

200 WARNINGS

- 201 NovoLog differs from regular human insulin by a more rapid onset and a shorter
- duration of activity. Because of the fast onset of action, the injection of NovoLog should
- 203 immediately be followed by a meal. Because of the short duration of action of NovoLog,
- 204 patients with diabetes also require a longer-acting insulin to maintain adequate glucose
- 205 control. Glucose monitoring is recommended for all patients with diabetes and is
- 206 particularly important for patients using external pump infusion therapy.
- 207
- 208 Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog.
- As with all insulins, the timing of hypoglycemia may differ among various insulin formulations.
- 210
- Any change of insulin dose should be made cautiously and only under medical
- supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH,
- analog), species (animal, human), or method of manufacture (rDNA versus animal-
- source insulin) may result in the need for a change in dosage.
- 216
- 217 Insulin Pumps: When used in an external insulin pump for subcutaneous infusion,
- 218 NovoLog should not be diluted or mixed with any other insulin. Physicians and patients
- 219 should carefully evaluate information on pump use in the NovoLog physician and patient
- 220 package inserts and in the pump manufacturer's manual (e.g. NovoLog-specific
- information should be followed for in-use time, frequency of changing infusion sets, or

- 222 other details specific to NovoLog usage, because NovoLog-specific information may
- differ from general pump manual instructions). 223
- 224

Pump or infusion set malfunctions or insulin degradation can lead to hyperglycemia and 225 226 ketosis in a short time because of the small subcutaneous depot of insulin. This is

- especially pertinent for rapid-acting insulin analogs that are more rapidly absorbed 227
- through skin and have shorter duration of action. These differences may be particularly 228
- relevant when patients are switched from multiple injection therapy or infusion with 229
- 230 buffered regular insulin. Prompt identification and correction of the cause of

DOSAGE AND ADMINISTRATION, and RECOMMENDED STORAGE.)

- hyperglycemia or ketosis is necessary. Interim therapy with subcutaneous injection may 231 be required. (See PRECAUTIONS, Mixing of Insulins, Information for Patients,
- 232

233

234

235 PRECAUTIONS

General 236

- Hypoglycemia and hypokalemia are among the potential clinical adverse effects associated 237
- with the use of all insulins. Because of differences in the action of NovoLog and other 238
- insulins, care should be taken in patients in whom such potential side effects might be 239
- clinically relevant (e.g., patients who are fasting, have autonomic neuropathy, or are using 240
- 241 potassium-lowering drugs or patients taking drugs sensitive to serum potassium level).
- Lipodystrophy and hypersensitivity are among other potential clinical adverse effects 242 associated with the use of all insulins. 243
- As with all insulin preparations, the time course of NovoLog action may vary in different 244
- individuals or at different times in the same individual and is dependent on site of injection, 245 blood supply, temperature, and physical activity. 246
- Adjustment of dosage of any insulin may be necessary if patients change their physical 247
- activity or their usual meal plan. Insulin requirements may be altered during illness, 248
- emotional disturbances, or other stresses. 249
- 250
- Hypoglycemia As with all insulin preparations, hypoglycemic reactions may be associated 251
- 252 with the administration of NovoLog. Rapid changes in serum glucose levels may induce
- symptoms of hypoglycemia in persons with diabetes, regardless of the glucose value. Early 253
- warning symptoms of hypoglycemia may be different or less pronounced under certain 254
- conditions, such as long duration of diabetes, diabetic nerve disease, use of medications such 255
- 256 as beta-blockers, or intensified diabetes control (see PRECAUTIONS, Drug Interactions).
- Such situations may result in severe hypoglycemia (and, possibly, loss of consciousness) prior 257
- to patients' awareness of hypoglycemia. 258
- 259
- *Renal Impairment* As with other insulins, the dose requirements for NovoLog® may be 260
- reduced in patients with renal impairment (see CLINICAL PHARMACOLOGY, 261
- Pharmacokinetics). 262
- 263
- Hepatic Impairment As with other insulins, the dose requirements for NovoLog® may be 264
- reduced in patients with hepatic impairment (see CLINICAL PHARMACOLOGY, 265
- Pharmacokinetics). 266

- 268 Allergy Local Allergy As with other insulin therapy, patients may experience redness,
- swelling, or itching at the site of injection. These minor reactions usually resolve in a few
- 270 days to a few weeks, but in some occasions, may require discontinuation of NovoLog. In
- some instances, these reactions may be related to factors other than insulin, such as irritants in
 a skin cleansing agent or poor injection technique.
- a skin cleansing agent or poor injection technique.
- 273 Systemic Allergy Less common, but potentially more serious, is generalized allergy to
- insulin, which may cause rash (including pruritus) over the whole body, shortness of breath,
- wheezing, reduction in blood pressure, rapid pulse, or sweating. Severe cases of generalized allergy, including anaphylactic reaction, may be life threatening.
- Localized reactions and generalized myalgias have been reported with the use of metacresol as an injectable excipient.
- In controlled clinical trials using injection therapy, allergic reactions were reported in 3 of 735
- patients (0.4%) who received regular human insulin and 10 of 1394 patients (0.7%) who
- received NovoLog. During these and other trials, 3 of 2341 patients treated with NovoLog
- were discontinued due to allergic reactions.
- 283
- Antibody Production Increases in levels of anti-insulin antibodies that react with both human
 insulin and insulin aspart have been observed in patients treated with NovoLog®. The
 number of patients treated with insulin aspart experiencing these increases is greater than the
 number among those treated with human regular insulin. Data from a 12-month controlled
- trial in patients with Type 1 diabetes suggest that the increase in these antibodies is transient.
- 289 The differences in antibody levels between the human regular insulin and insulin aspart
- treatment groups observed at 3 and 6 months were no longer evident at 12 months. The
- clinical significance of these antibodies is not known. They do not appear to cause
- deterioration in HbA1c or to necessitate increases in insulin dose.
- 293
- 294 Pregnancy and Lactation
- Female patients should be advised to tell their physician if they intend to become, or if they become pregnant. Information is not available on the use of NovoLog during pregnancy or lactation.
- 298
- 299 Usage in Pumps
- 300
- **301 Pumps:**
- 302 NovoLog is recommended for use in Disetronic H-TRON series, MiniMed 500 series, and
- 303 other equivalent pumps.
- 304

305 (**Reservoirs**) and infusion sets:)

NovoLog is recommended for use in any reservoir and infusion sets that are compatible with
insulin and the specific pump. In-vitro studies have shown that pump malfunction, loss of
metacresol, and insulin degradation, may occur when NovoLog is maintained in a pump
system for more than 48 hours. Reservoirs and infusion sets should be changed at least every
48 hours.

311

NovoLog in clinical use should not be exposed to temperatures greater than 37°C (98.6°F).
NovoLog should not be mixed with other insulins or with a diluent when it is used in the
pump. (See WARNINGS, PRECAUTIONS, Mixing of Insulins, Information for Patients,

- pump. (See WARNINGS, PRECAUTIONS, Mixing of Insulins, Information
 DOSAGE AND ADMINISTRATION, and RECOMMENDED STORAGE.)
- 316
- 317 **Information for Patients**
- 318

319 *For all patients:*

320 Patients should be informed about potential risks and advantages of NovoLog therapy including the possible side effects. Patients should also be offered continued education and 321 advice on insulin therapies, injection technique, life-style management, regular glucose 322 323 monitoring, periodic glycosylated hemoglobin testing, recognition and management of hypoand hyperglycemia, adherence to meal planning, complications of insulin therapy, timing of 324 dose, instruction in the use of injection or subcutaneous infusion devices, and proper storage 325 of insulin. Patients should be informed that frequent, patient-performed blood glucose 326 measurements are needed to achieve optimal glycemic control and avoid both hyper- and 327 hypoglycemia. 328

329

Female patients should be advised to tell their physician if they intend to become, or if they become pregnant. Information is not available on the use of NovoLog during pregnancy or lactation (see PRECAUTIONS, Pregnancy).

333

334 For patients using pumps

Patients using external pump infusion therapy should be trained in intensive insulin therapy with multiple injections and in the function of their pump and pump accessories.

337

338 **Pumps:**

NovoLog is recommended for use in Disetronic H-TRON series, MiniMed 500 series, and
 other equivalent pumps

341

342 **Reservoirs and infusion sets:**

NovoLog is recommended for use in any reservoir and infusion sets that are compatible with insulin and the specific pump. Please see recommended reservoir and infusion sets in the pump manual.

- 346
- 347 To avoid insulin degradation, infusion set occlusion, and loss of the preservative
- 348 (metacresol), reservoirs, infusion sets, and injection site should be changed at least every
- **48 hours.**

350

351

352 Insulin exposed to temperatures higher than 37°C (98.6°F) should be discarded. The

temperature of the insulin may exceed ambient temperature when the pump housing, cover,

tubing, or sport case is exposed to sunlight or radiant heat. Infusion sites that are

erythematous, pruritic, or thickened should be reported to medical personnel, and a new site

selected because continued infusion may increase the skin reaction and/or alter the absorption

of NovoLog. Pump or infusion set malfunctions or insulin degradation can lead to

- hyperglycemia and ketosis in a short time because of the small subcutaneous depot of insulin.
- This is especially pertinent for rapid-acting insulin analogs that are more rapidly absorbed through skin and have shorter duration of action. These differences are particularly relevant
- when patients are switched from infused buffered regular insulin or multiple injection therapy.

362 Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary.

- 363 Problems include pump malfunction, infusion set occlusion, leakage, disconnection or
- 364 kinking, and degraded insulin. Less commonly, hypoglycemia from pump malfunction may
- 365 occur. If these problems cannot be promptly corrected, patients should resume therapy with
- 366 subcutaneous insulin injection and contact their physician. (See WARNINGS,
- 367 PRECAUTIONS, Mixing of Insulins, DOSAGE AND ADMINISTRATION, and
- 368 RECOMMENDED STORAGE.)

369

370 Laboratory Tests

371 As with all insulin therapy, the therapeutic response to NovoLog should be monitored by

- 372 periodic blood glucose tests. Periodic measurement of glycosylated hemoglobin is
- recommended for the monitoring of long-term glycemic control.
- 374

375 **Drug Interactions**

- A number of substances affect glucose metabolism and may require insulin dose adjustment
 and particularly close monitoring.
- The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors,
- disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene,
 salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
- The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thuraid hormonog, estragong, progestogong (a.g., in eral contracentives)
- thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
- Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the
 blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycemia, which
 may sometimes be followed by hyperglycemia.
- In addition, under the influence of sympatholytic medicinal products such as beta blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be
 reduced or absent (see CLINICAL PHARMACOLOGY).
- 392

393 Mixing of Insulins

- A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog 394 • with NPH human insulin immediately before injection produced some attenuation in the 395 peak concentration of NovoLog, but that the time to peak and the total bioavailability of 396 NovoLog were not significantly affected. If NovoLog is mixed with NPH human insulin, 397 398 NovoLog should be drawn into the syringe first. The injection should be made immediately after mixing. Because there are no data on the compatibility of NovoLog and 399 crystalline zinc insulin preparations, NovoLog should not be mixed with these 400 401 preparations.
- The effects of mixing NovoLog with insulins of animal source or insulin preparations
 produced by other manufacturers have not been studied (see WARNINGS).
- Mixtures should not be administered intravenously.
- When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.

408 Carcinogenicity, Mutagenicity, Impairment of Fertility

Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the 409 carcinogenic potential of NovoLog. In 52-week studies, Sprague-Dawley rats were dosed 410 subcutaneously with NovoLog at 10, 50, and 200 U/kg/day (approximately 2, 8, and 32 times 411 412 the human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area, respectively). At a dose of 200 U/kg/day, NovoLog increased the incidence of mammary gland tumors in 413 females when compared to untreated controls. The incidence of mammary tumors for 414 415 NovoLog was not significantly different than for regular human insulin. The relevance of these findings to humans is not known. NovoLog was not genotoxic in the following tests: 416 Ames test, mouse lymphoma cell forward gene mutation test, human peripheral blood 417 lymphocyte chromosome aberration test, in vivo micronucleus test in mice, and in ex vivo 418 419 UDS test in rat liver hepatocytes. In fertility studies in male and female rats, at subcutaneous doses up to 200 U/kg/day (approximately 32 times the human subcutaneous dose, based on 420 U/body surface area), no direct adverse effects on male and female fertility, or general 421 422 reproductive performance of animals was observed.

423

424 Pregnancy - Teratogenic Effects - Pregnancy Category C

There are no adequate well-controlled clinical studies of the use of NovoLog in pregnant women. NovoLog should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

428

429 It is essential for patients with diabetes or history of gestational diabetes to maintain good

430 metabolic control before conception and throughout pregnancy. Insulin requirements may
 431 decrease during the first trimester, generally increase during the second and third trimesters,

- and rapidly decline after delivery. Careful monitoring of glucose control is essential in such
 patients.
- 434

435 Subcutaneous reproduction and teratology studies have been performed with NovoLog and

- 436 regular human insulin in rats and rabbits. In these studies, NovoLog was given to female rats
- 437 before mating, during mating, and throughout pregnancy, and to rabbits during organogenesis.
- The effects of NovoLog did not differ from those observed with subcutaneous regular human

- 439 insulin. NovoLog, like human insulin, caused pre- and post-implantation losses and
- 440 visceral/skeletal abnormalities in rats at a dose of 200 U/kg/day (approximately 32 times the
- 441 human subcutaneous dose of 1.0 U/kg/day, based on U/body surface area) and in rabbits at a
- dose of 10 U/kg/day (approximately three times the human subcutaneous dose of 1.0
- 443 U/kg/day, based on U/body surface area). The effects are probably secondary to maternal
- 444 hypoglycemia at high doses. No significant effects were observed in rats at a dose of 50
- 445 U/kg/day and rabbits at a dose of 3 U/kg/day. These doses are approximately 8 times the
- 446 human subcutaneous dose of 1.0 U/kg/day for rats and equal to the human subcutaneous dose
- 447 of 1.0 U/kg/day for rabbits, based on U/body surface area.
- 448

449 Nursing Mothers

- 450 It is unknown whether insulin aspart is excreted in human milk. Many drugs, including
- human insulin, are excreted in human milk. For this reason, caution should be exercised when
 NovoLog is administered to a nursing mother.
- 453

454 **Pediatric Use**

- 455 Safety and effectiveness of NovoLog in children have not been studied.
- 456

457 Geriatric Use

- 458 Of the total number of patients (n=1,375) treated with NovoLog in 3 human insulin-controlled 459 clinical studies, 2.6% (n=36) were 65 years of age or over. Half of these patients had Type 1
- diabetes (18/1285) and half had Type 2 (18/90) diabetes. The HbA1c response to NovoLog,
- 461 as compared to human insulin, did not differ by age, particularly in patients with Type 2
- diabetes. Additional studies in larger populations of patients 65 years of age or over are
- 462 diabetes. Additional studies in larger populations of patients of years of age of over are 463 needed to permit conclusions regarding the safety of NovoLog in elderly compared to younger
- patients. Pharmacokinetic/pharmacodynamic studies to assess the effect of age on the onset of
- 465 NovoLog action have not been performed.
- 466

467468 ADVERSE REACTIONS

- 469 Clinical trials comparing NovoLog with regular human insulin did not demonstrate a
- 470 difference in frequency of adverse events between the two treatments.
- 471 Adverse events commonly associated with human insulin therapy include the following:
- 472 Body as Whole *Allergic reactions* (see PRECAUTIONS, Allergy).
- 473 Skin and Appendages Injection site reaction, lipodystrophy, pruritus, rash (see
- 474 PRECAUTIONS, Allergy; Information for Patients, Usage in Pumps).
- 475 **Other** *Hypoglycemia, Hyperglycemia and ketosis* (see WARNINGS and PRECAUTIONS).
- 476 In controlled clinical trials, small, but persistent elevations in alkaline phosphatase result were
- observed in some patients treated with NovoLog. The clinical significance of this finding isunknown.
- 479

480 **OVERDOSAGE**

- 481 Hypoglycemia may occur as a result of an excess of insulin relative to food intake, energy
- expenditure, or both. Mild episodes of hypoglycemia usually can be treated with oral glucose.
- 483 Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes

with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous
 glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation
 may be necessary because hypoglycemia may recur after apparent clinical recovery.

487

488 **DOSAGE AND ADMINISTRATION**

- NovoLog should generally be given immediately before a meal (start of meal within 5 to 10
- 490 minutes after injection) because of its fast onset of action. The dosage of
- 491 NovoLog should be individualized and determined, based on the physician's advice, in
- 492 accordance with the needs of the patient. The total daily individual insulin requirement is
- usually between 0.5 to1.0 units/kg/day. When used in a meal-related subcutaneous injection
 treatment regimen, 50 to 70% of total insulin requirements may be provided by NovoLog and
- 494 the remainder provided by an intermediate-acting or long-acting insulin. When used in
- 496 external insulin infusion pumps, the initial programming of the pump is based on the total
- 497 daily insulin dose of the previous regimen. Although there is significant interpatient
- variability, approximately 50% of the total dose is given as meal-related boluses of NovoLog
- and the remainder as basal infusion. Because of NovoLog's comparatively rapid onset and
- short duration of glucose lowering activity, some patients may require more basal insulin and
- more total insulin to prevent pre-meal hyperglycemia when using NovoLog than when using
- human regular insulin. Additional basal insulin injections, or higher basal rates in external
- subcutaneous infusion pumps may be necessary. NovoLog in the reservoir and infusion
 sets, and the injection site must be changed at least every 48 hours.
- NovoLog should be administered by subcutaneous injection in the abdominal wall, the thigh,
- or the upper arm, or by continuous subcutaneous infusion in the abdominal wall. Injection
- sites and infusion sites should be rotated within the same region. As with all insulins, the
- duration of action will vary according to the dose, injection site, blood flow, temperature, andlevel of physical activity.
- 510 Parenteral drug products should be inspected visually for particulate matter and discoloration
- 511 prior to administration, whenever solution and container permit. Never use any NovoLog if it
- 512 has become viscous (thickened) or cloudy; use it only if it is clear and colorless. NovoLog
- should not be used after the printed expiration date.
- 514

515 HOW SUPPLIED

- 516 NovoLog is available in the following package sizes: each presentation containing 100 Units 517 of insulin aspart per mL (U-100).
- 518 10 mL vials NDC 0169-7501-11
- 519 3 mL PenFill[®] cartridges* NDC 0169-3303-12
- 5203 mL NovoLog FlexPen® Prefilled syringeNDC 0169-6339-10
- 521 3 mL NovoLog InnoLet[®] Prefilled syringe NDC 0169-xxxx-xx
- 522
- * NovoLog PenFill cartridges are for use with NovoFine[®] disposable needles and the
- 524 following Novo Nordisk 3 mL PenFill cartridge compatible insulin delivery devices:
- 525 NovoPen[®]3, NovoPen Junior, Innovo[®], and InDuo[®].
- 526 NovoLog FlexPen Prefilled syringes are for use with NovoFine disposable needles.
- 527 **RECOMMENDED STORAGE**

- 528 NovoLog in unopened vials, cartridges, NovoLog FlexPen, and NovoLog InnoLet Prefilled
- syringes should be stored between 2° and 8° C (36° to 46° F). *Do not freeze*. **Do not use**
- 530 NovoLog if it has been frozen or exposed to temperatures that exceed 37°C (98.6°F). After
- a vial, cartridge, or Prefilled syringe has been punctured, it may be kept at temperatures below
- 30° C (86° F) for up to 28 days, but should not be exposed to excessive heat or sunlight. Opened
- vials may be refrigerated. Cartridges should not be refrigerated after insertion into the Novo
- Nordisk 3 mL PenFill® cartridge compatible insulin delivery devices. The infusion set (tubing
- and needle) should be changed at least every 48 hours.
- 536
- 537 NovoLog in the reservoir should be discarded after at least every 48 hours of use or after
- exposure to temperatures that exceed $37^{\circ}C$ (98.6°F).
- 539

	Not in-use (unopened) Room Temperature (below 30° C)	Not in-use (unopened) Refrigerated	In-use (opened) Room Temperature (below 30° C)
10 mL vial	28 days	Until expiration date	28 days (refrigerated/room temperature)
3 mL PenFill cartridges	28 days	Until expiration date	28 days (Do not refrigerate)
3 mL NovoLog FlexPen	28 days	Until expiration date	28 days (Do not refrigerate)
3 mL NovoLog InnoLet	28 days	Until expiration date	28 days (Do not refrigerate)

- 541 542 Rx only
- 543
- 544 Date of Issue: XX xx, 2004

545 8-XXXX-XX-XXX-X

- 546
- 547 Manufactured For Novo Nordisk Pharmaceuticals Inc., Princeton, New Jersey 08540
- 548 Manufactured By Novo Nordisk A/S, 2880 Bagsvaerd, Denmark
- 549
- 550551 www.novonordisk-us.com
- 552
- 553 NovoLog[®], NovoPen[®] 3, PenFill[®], Novolin[®], FlexPen[®], Innovo[®], InnoLet[®], and NovoFine[®]
- are trademarks of Novo Nordisk A/S
- 555 InDuo[®] is a trademark of LifeScan, Inc., a Johnson & Johnson company.
- 556 $\operatorname{H-TRON}^{\operatorname{TM}}$ is a trademark of Disetronic Medical Systems, Inc.
- 557

1						
2	Information For The Patient					
3	NovoLog [®] (Insulin aspart [rDNA origin] Injection)					
4	3 mL PenFill [®] Disposable Cartridge (300 units per cartridge)					
5	10 mL Vial (1000 units per vial)					
6 7	100 units/mL (U-100)					
8	• What is the most important information I should know about NovoLog?					
9	• For all NovoLog users					
10	• For pump users					
11	• What is NovoLog?					
12	• Who should not use NovoLog?					
13	What should I know about using insulin?					
14	• What should I know about using NovoLog?					
15	• What should I avoid when using NovoLog?					
16	• What are the possible side effects of NovoLog?					
17	• How should I store NovoLog?					
18	• General advice					
19	• Injection and pump infusion instructions					
20	• How should I inject NovoLog?					
21	• Using Vials					
22	• Using Cartridges					
23	• How should I infuse NovoLog with an external subcutaneous insulin infusion					
24	pump?					
25	How should I mix insulins?					
26						
27	Read this information carefully before you begin treatment. Read the information you					
28	get whenever you get more medicine. There may be new information. This information					
29	does not take the place of talking with your doctor about your medical condition or your					
30	treatment. If you have any questions about NovoLog [®] (NO-voe-log), ask your doctor.					
31	Only your doctor can determine if NovoLog [®] is right for you.					
32						
33	What is the most important information I should know about NovoLog?					
34 25	For All NovaL og Llagua					
35	For All NovoLog Users					
36 37	• NovoLog (NO-voe-log) is different from regular human insulin and buffered regular human insulin (Velosulin). It works faster (rapid onset of action) and will not work as					
38	long (shorter duration of action) as regular human insulin or buffered regular human					
38 39	insulin (Velosulin).					
40	insum (verosum).					
41	• Because the onset of action is fast, you should eat a meal 5 to 10 minutes after a					
42	NovoLog injection or NovoLog bolus infusion dose given by an external pump. (A					
43	bolus is a large dose.) Eating right after the dose will reduce the risk of low blood					
44	sugar (hypoglycemia).					
45						

- The shorter duration of NovoLog's action means that you may need to use an 46 intermediate or longer-acting insulin (basal insulin) or higher basal rates of NovoLog 47 insulin infusion in the pump. This will give the best glucose control and will help you 48 49 avoid hyperglycemia (high blood sugar) and ketoacidosis (too much acid [low pH] in your body). 50
- 51 52
- Glucose monitoring is recommended for all patients who use insulin.
- 53

56

57

If you use NovoLog by injection, you may need to increase some or all of the following: 54

- your total dose of insulin
- your dose of intermediate or long-acting insulin (for example, NPH)
- the number of injections of basal insulin
- 58 If you infuse NovoLog into the skin (subcutaneous tissue) by pump, you may need to 59 increase some or all of the following: 60
- your total insulin dose 61
 - the basal infusion dose
- the proportion of total insulin given as a basal infusion 63
- 64

62

- Age and exposure to heat affect the stability of NovoLog and its preservative. Also, 65 NovoLog does not work well after it has been frozen. Therefore, do not use old insulin or 66 insulin that has been exposed to temperature extremes. Hyperglycemia may be a sign that 67 the insulin is no longer working and needs to be replaced. 68
- 69 70 Do not mix NovoLog:
 - with any other insulins when used in a pump
- 71 • with Lantus[®] (insulin glargine [rDNA origin] injection) when used with injections 72 by syringe 73
- 74 (You may, however, mix NovoLog with NPH when used with injections by syringe.
- See: How should I mix insulins?) 75
- 76 For Pump Users 77
- 78 Glucose monitoring is very important for patients using external pump subcutaneous infusion therapy. You should be aware that pump or infusion set malfunctions that 79 result in inadequate insulin infusion can quickly lead to hyperglycemia and ketosis. 80 Accordingly, problems with the infusion pump, the flow of insulin, or the quality of 81 the insulin should be identified and corrected as quickly as possible. There is only a 82 small amount of insulin infused into the skin with a pump. The faster absorption 83 through the skin of rapid-acting insulin analogs and shorter duration of action may 84 give you less time to identify and correct the problem than with buffered regular 85 insulin. 86 87
- 88 Therefore, you should dose with insulin from a new vial of NovoLog if unexplained hyperglycemia or pump alarms do not respond to all of the following: 89
- a repeat dose (injection or bolus) of NovoLog 90

91	• a change in the infusion set, including the NovoLog in the reservoir
92	• a change in the infusion site
93	
94	If these measures do not work, you may need to resume skin (subcutaneous)
95	injections with syringes or insulin pens. Continue to monitor your glucose and
96	ketones. If problems continue, you must contact your doctor.
97	
98	• When NovoLog is used in an external subcutaneous insulin infusion pump, you
99	should use only recommended pumps. Reservoirs, infusion sets, and injection site
100	should be changed at least every 48 hours. In addition, the reservoir, the infusion set,
101	and infusion site should be changed:
102	• with unexpected hyperglycemia or ketosis
103	• when the alarm sounds, as specified by your pump manual
104	• if the insulin or pump has been exposed to temperatures over 98.6°F (37°C), such
105	as in a sauna, with long showers, or on a hot day
106	• if the insulin or pump could have absorbed radiant heat, for example from
107	sunlight, that would heat the insulin to over 98.6°F (37°C). Dark colored pump
108	cases or sport covers can increase this type of heat. The location where the pump
109	is worn may also affect the temperature
110	
111	Patients who develop "pump bumps" (skin reactions at the infusion site) may need to
112	change infusion sites more often than every 48 hours.
113	
114	For your safety, read the section "What are the possible side effects of NovoLog?" to
115	review the symptoms of low blood sugar (hypoglycemia) and high blood sugar
116	(hyperglycemia).
117	
118	What is NovoLog?
119	NovoLog is a clear, colorless, sterile solution for injection or infusion under the skin
120	(subcutaneously). NovoLog is a human-made form of insulin to lower your blood sugar
121	faster than human regular insulin. Because the insulin is human-made by recombinant
122	DNA technology (rDNA) and is chemically different from the insulin made by the human
123	body, it is called an insulin analog. The active ingredient in NovoLog is insulin aspart.
124	The concentration of insulin aspart is 100 units per milliliter, or U100. NovoLog also
125	contains: glycerin, phenol, metacresol, zinc, disodium hydrogen phosphate dihydrate,
126	and sodium chloride. Hydrochloric acid and/or sodium hydroxide may be added to adjust
127	the pH. These ingredients help to preserve or stabilize NovoLog insulin. The pH
128	(balance between acid and alkaline conditions) is important to the stability of NovoLog.
129	Increases in temperature can affect the stability of NovoLog, so it may not work well.
130	
131	Who should not use NovoLog?
132	Do not use NovoLog if:
133	 your blood sugar (glucose) is too low (hypoglycemia)
134	• you do not plan to eat right after your injection or infusion

• you do not plan to eat right after your injection or infusion

	1 age 4
135 136 137	• you are allergic to insulin aspart or any of the ingredients contained in NovoLog (check with your doctor if you are not sure)
138 139 140 141	The effects of NovoLog on an unborn child or on a nursing baby are unknown. Therefore, tell your doctor if you plan to become pregnant or breast feed, or if you become pregnant. You may need to use another medicine.
142 143 144 145	Tell your doctor about all medicines and supplements that you are using. Some medicines, including non-prescription medicines and dietary supplements, may affect your diabetes.
146 147 148 149 150 151 152 153 154 155 156	 What should I know about using insulin? Make any change of insulin cautiously and only under medical supervision. Changes in the strength, manufacturer, type (for example: Regular, NPH, Lente[®]), species (beef, pork, beef-pork, human) or method of manufacture (recombinant [rDNA] or animal source insulin) may cause a need for a change in the timing or dose of the new insulin. Glucose monitoring will help you and your health care provider adjust dosages. Always carry a quick source of sugar, such as candy or glucose tablets, to treat low blood sugars (hypoglycemia). Always carry identification that states that you have diabetes.
157 158 159 160	What should I know about using NovoLog? See the end of this Patient Information for instructions for using NovoLog in injections and pumps.
161 162 163 164 165	• NovoLog starts working 10 to 20 minutes after injection or infusion. The greatest blood sugar lowering effect is between 1 and 3 hours after injection or infusion. This blood sugar lowering lasts for 3 to 5 hours. (The time periods are only general guidelines.)
166 167 168 169	• Because the onset of action is rapid, you should eat a meal within 5to10 minutes after a NovoLog injection or a NovoLog bolus dose from an external pump to avoid low blood sugar (hypoglycemia).
170 171 172 173 174	• The shorter duration of NovoLog's action means that you may need to use an intermediate or longer-acting insulin (basal insulin) or higher basal rates of NovoLog insulin infusion in the pump. This will help you avoid hyperglycemia and ketoacidosis.
174 175 176 177 178	• Do not inject or infuse in skin that has become reddened or bumpy or thickened after infusion or injection. Insulin absorption in these areas may not be the same as that in normal skin, and may change the onset and duration of insulin action.

•

cloudy, thickened, or colored, or if it contains solid particles. 180 181 182 What should I avoid while using NovoLog? 183 • Drinking alcohol may lead to hypoglycemia. Do not miss meals after injections of NovoLog or bolus infusions of NovoLog. 184 • 185 What are the possible side effects of NovoLog? 186 Insulins can cause hypoglycemia (low blood sugar), hyperglycemia (high blood sugar), 187 allergy, and skin reactions. 188 189 Hypoglycemia (low blood sugar). This is the most common side effect. It occurs when 190 there is a conflict between the amount of carbohydrates (source of glucose) from your 191 food, the amount of glucose used by your body, and the amount and timing of insulin 192 dosing. Therefore, hypoglycemia can occur with: 193 The wrong insulin dose. This can happen with any of the following: 194 too much insulin is injected 195 • • the bolus dose of insulin infusion is set too high 196 the basal infusion dose is set too high 197 • the pump does not work right, delivering too much insulin 198 • Medicines that directly lower glucose or increase sensitivity to insulin. This can 199 200 happen with oral (taken by mouth) antidiabetes drugs, sulfa antibiotics (for infections), ACE inhibitors (for blood pressure and heart failure), salicylates, 201 including aspirin and NSAIDS (for pain), some antidepressants, and with other 202 203 medicines. Medical conditions that limit the body's glucose reserve, lengthen the time 204 insulin stays in the body, or that increase sensitivity to insulin. These conditions 205 include diseases of the adrenal glands, the pituitary, the thyroid gland, the liver, and 206 207 the kidney. Not enough carbohydrate (sugar or starch) intake. This can happen if: 208 a meal or snack is missed or delayed 209 • you have vomiting or diarrhea that decreases the amount of glucose absorbed by 210 your body 211 • alcohol interferes with carbohydrate metabolism 212 Too much glucose use by the body. This can happen from: 213 too much exercise 214 • higher than normal metabolism rates due to fever or an overactive thyroid 215 • 216 Hypoglycemia can be mild or severe. Its onset may be rapid. Patients with very good 217 (tight) glucose control, patients with diabetic neuropathy (nerve problems), or patients 218 using some Beta-blockers (used for high blood pressure and heart conditions) may have 219 few warning symptoms before severe hypoglycemia develops. Hypoglycemia may reduce 220 your ability to drive a car or use mechanical equipment without risk of injury to yourself 221 or others. Severe hypoglycemia can cause temporary or permanent harm to your heart or 222

Use NovoLog only if it appears clear and colorless. Do not use NovoLog if it appears

- brain. It may cause unconsciousness, seizures, or death. Symptoms of hypoglycemia
- 224 include:
- anxiety, irritability, restlessness, trouble concentrating, personality changes, mood changes, or other abnormal behavior
- tingling in your hands, feet, lips, or tongue
- dizziness, light-headedness, or drowsiness
- nightmares or trouble sleeping
- headache
- blurred vision or slurred speech
- palpitations (rapid heart beat)
- sweating
- tremor (shaking) or unsteady gait (walking)
- 235

Mild to moderate hypoglycemia can be treated by eating or drinking carbohydrates (milk, orange juice, sugar candies, or glucose tablets). More severe or continuing hypoglycemia may require the help of another person or emergency medical personnel. Patients who are unable to take sugar by mouth or who are unconscious may need treatment with a

- 240 glucagon injection or glucose given intravenously (in the vein).
- 241
- Talk with your doctor about severe, continuing, or frequent hypoglycemia, and
- 243 hypoglycemia for which you had few warning symptoms.
- 244

250

251

252

253

Hyperglycemia (high blood sugar) is another common side effect. It also occurs when
there is a conflict between the amount of carbohydrates (source of glucose) from your
food, the amount of glucose used by your body, and the amount and timing of insulin
dosing. Therefore, hyperglycemia can occur with:

- **The wrong insulin dose.** This can happen from any of the following:
 - too little or no insulin is injected
 - the bolus dose of insulin infusion is set too low
 - the basal infusion dose is set too low
 - the pump or catheter system does not work right, delivering too little insulin
- the insulin's ability to lower glucose is changed by incorrect storage (freezing, excessive heat), or usage after the expiration date
- Medicines that directly increase glucose or decrease sensitivity to insulin. This
 can happen, for example, with thiazide water pills (used for blood pressure),
 corticosteroids, birth control pills, and protease inhibitors (used for AIDS).
- Medical conditions that increase the body's production of glucose or decrease
 sensitivity to insulin. These medical conditions include fevers, infections, heart
 attacks, and stress.
- **Too much carbohydrate intake**. This can happen if you
- eat larger meals
- eat more often
- increase the proportion of carbohydrate in your meals
- 266

267 Hyperglycemia can be mild or severe. It can **progress to diabetic ketoacidosis (DKA)**

or very high glucose levels (hyperosmolar coma) and result in unconsciousness and

death. Although DKA occurs most often in patients with Type 1 diabetes, it can occur in

270 patients with Type 2 diabetes who become severely ill. Urine or blood tests will show

acetone, ketones, and high levels of glucose. Hyperosmolar coma occurs most often in

- patients with Type 2 diabetes. Urine and blood tests will show very high levels of
- 273 glucose.

Glucose monitoring is very important for patients using external pump infusion therapy.

275 You should be aware that pump or infusion set malfunctions that result in inadequate

insulin infusion can quickly lead to hyperglycemia and ketosis. Accordingly, problems

with the infusion pump, the flow of insulin, or the quality of the insulin should be

- identified and corrected as quickly as possible. The faster absorption of rapid-acting
- insulin analogs through the skin and shorter duration of action may give you less time toidentify and correct the problem.
- 281 Because some patients experience few symptoms of hyperglycemia and ketosis, it is
- important to monitor your glucose several times a day. Symptoms of hyperglycemiainclude:
- confusion or drowsiness
- fruity smelling breath
- rapid, deep breathing
- increased thirst
- decreased appetite, nausea, or vomiting
- e abdominal (stomach area) pain
- 290 rapid heart rate
- increased urination and dehydration (too little fluid in your body)
- 292

Mild hyperglycemia can be treated by extra doses of insulin and drinking fluids

(rehydration). Patients using pumps should check pump function and replace the insulinin the reservoir-syringe, as well as change the tubing and catheter and the infusion site.

296 Patients using pumps may need to resume insulin injections with syringes or

- injection pens. Glucose and acetone-ketone levels should be monitored more often until
- 298 they return to normal. More severe or continuing hyperglycemia requires prompt
- evaluation and treatment by your health care provider.
- 300
- 301 **Allergy can be serious.** Generalized allergy is an uncommon, but possibly life-302 threatening, reaction to insulin products. Symptoms include:
- itchy rash over the entire body
- shortness of breath or wheezing
- 305 confusion
- 306 low blood pressure
- 307 rapid heart beat
- 308 sweating
- 309 If you think you are having a generalized allergic reaction, get emergency medical
- 310 help right away.
- 311

Allergic reactions at the injection site (itching, redness, hardness, or swelling) are more common than generalized allergy. They may need several days or weeks to clear up. Pump patients with site reactions may need to change their infusion sites more often than every 48 hours. Patients should avoid injection or infusion of insulin into skin areas that have reactions. Tell your doctor about such reactions, because they can become more severe, or they may change the absorption of insulin.

318

Lipodystrophy is a common change in the fat below the injection site. These changes include loss of fat (depressions in the skin called lipoatrophy) or thickening of the tissue under the skin (lipohypertrophy). Pump patients with lipodystrophy may need to change their infusion sites more often than every 48 hours. Patients should avoid injection or infusion of insulin into skin areas that have these reactions. Tell your doctor about such reactions because they can become more severe, or they may change the absorption of insulin.

326

327 How should I store NovoLog?

- NovoLog can be damaged by high temperatures. Therefore, be sure to protect it from high air temperatures, heat from the sun, saunas, long showers, and other heat sources. This is especially important if you use a pump or an insulin pen, because you carry these devices with you and they may be exposed to different temperatures as you go about your daily activities. Throw NovoLog away if it has been in temperatures greater than 98.6°F (37°C).
- 334

Unopened NovoLog should be stored in a refrigerator but not in the freezer and protected from light. Even if it has been refrigerated and protected from sunlight and unopened, it should not be used after the expiration date on the label and the carton.
 Unopened vials and cartridges can be stored unrefrigerated at temperatures below 86°F (30°C) and protected from light for up to 28 days.

- 340
- Punctured vials and cartridges can be stored unrefrigerated at temperatures below 86°F (30°C) and protected from light for up to 28 days. Punctured vials may be stored in the refrigerator. Cartridges inserted into their NovoPen[®] 3 device should not be stored in the refrigerator.
- 345
- The NovoLog in the pump reservoir and the complete infusion set (reservoir, tubing, catheter-needle) should be replaced at least every 48 hours. Replacement should be more often than every 48 hours if you have hyperglycemia, the pump alarm sounds, or the insulin flow is blocked (occlusion).
- 350

352

- Never use NovoLog if it has been stored improperly.
- 353 General advice
- This leaflet summarizes the most important information about NovoLog. If you would
- like more information, talk with your doctor. You can ask your pharmacist or doctor for
- information about NovoLog that is written for health professionals.

357	
358	Injection and pump infusion instructions
359	 NovoLog comes in 10 mL (milliliter) vials or in 3 mL cartridges. NovoLog can be
360	withdrawn from vials with syringes for injection or for insertion into the reservoirs of
	external subcutaneous infusion pumps (Disetronic H-TRON [®] series, MiniMed 500
361	
362	series, or other pumps recommended by your doctor.)
363	• Doses of insulin are measured in units. NovoLog is available as a U-100 insulin.
364 365	One milliliter (mL) of U-100 contains 100 units of insulin aspart (1 mL=1 cc). Only U-100 type syringes should be used for injection to ensure proper dosing.
366	 Disposable syringes and needles are sterile if the package is sealed. They should be
367	used only once and thrown away properly, to protect others from harm.
368	• NovoLog PenFill [®] cartridges are for use with NovoFine [®] disposable needles and the
369	following Novo Nordisk 3 mL PenFill® compatible insulin delivery devices:
370	NovoPen [®] 3, NovoPen [®] Junior, Innovo [®] , and InDuo [®] . Never share needles.
371	
372	How should I inject NovoLog?
373	Univer Vinla
374	Using Vials
375 376	1. The vial and the insulin should be inspected. The insulin should be clear and colorless. The tamper-resistant cap should be in place to be removed by you. If the cap had been
	removed before your first use of the vial, or if the insulin is cloudy or colored, you
377	should return the vial to the pharmacy. Do not use it.
378	1 2
379	2. Both the injection site and your hands should be cleaned with soap and water or with alcohol. The injection site should be dry before you inject.
380	 The rubber stopper should be wiped with an alcohol wipe.
381 382	
382 383	4. The plunger of the syringe should be pulled back until the black tip is at the level for the number of units to be injected.
384	5. Insert the needle of the syringe through the rubber stopper of the vial. Push in the
385	syringe plunger completely to put air into the vial.
386	6. Turn the vial upside-down with the needle-syringe still attached, and pull the plunger
387	back a few units past the correct dose.
388	7. Remove any air bubbles by flicking the syringe and squirting air bubbles out the
389	needle. Continue pushing the plunger until you have the correct dose.
390	8. Lift the vial off the syringe.
391	9. Inject NovoLog into the subcutaneous (under the skin) tissue (not into muscle or
392	blood vessels) in the abdomen, thighs, upper arms, or buttocks. Pinch the skin fold
393	between your fingers and push the needle straight into the pinched skin. Because
394	insulin absorption and activity can be affected by the site you choose, you should
395	discuss the injection site with your doctor.
396	10. Release the pinched skin and push the plunger in completely. Keep the needle in the
397	skin for a few seconds before withdrawing the syringe.
398	11. Press the injection site for a few seconds to reduce bleeding. Do not rub.
399	12. To avoid needle sticks, throw away the syringe and needle without recapping. Discuss
400	sterile technique and proper disposal of your used insulin supplies with your doctor

400 sterile technique and proper disposal of your used insulin supplies with your doctor.

Using Cartridges 402 1. The cartridge and the insulin should be inspected. The insulin should be clear and 403 colorless. The tamper-resistant foil should be in place to be removed by you. If the 404 foil had been punctured or removed before your first use of the cartridge or if the 405 insulin is cloudy or colored, you should return the cartridge to the pharmacy. Do not 406 407 use it. 2. Both the injection site and your hands should be cleaned with soap and water or with 408 alcohol. The injection site should be dry before you inject. Do not use skin that is 409 reddened, itchy, or thickened as an infusion site. 410 3. Insert a 3 mL cartridge in the pen-device barrel. Attach a new needle to the end of the 411 cartridge and turn the pen device upside-down so that any air bubbles can be 412 eliminated by flicking the pen device and squirting air bubbles out the needle. (This 413 should eliminate extra air for all future doses from that cartridge. However, the needle 414 will need to be changed for each dose.) 415 416 4. Set the dose to be delivered by twisting the top of the pen-device until the correct number appears in the window. 417 5. Inject NovoLog into the subcutaneous (under the skin) tissue (not into muscle or 418 blood vessels) in the abdomen, thighs, upper arms, or buttocks. Pinch the skin fold 419 between your fingers and push the needle straight into the pinched skin. Because 420 insulin absorption and activity can be affected by the site you choose, you should 421 422 discuss the injection site with your doctor. 6. Release the pinched skin. Inject the dose by pressing the flat plunger button on the 423 424 top of the pen-device. Keep the needle in the skin for a few seconds before 425 withdrawing the pen-device. 426 7. Press the injection site for a few seconds to reduce bleeding. **Do not rub.** 8. Throw away the disposable needle without recapping to avoid needle sticks. Discuss 427 sterile technique and proper disposal of your used insulin supplies with your doctor. 428 429 How should I infuse NovoLog with an external subcutaneous insulin infusion pump? 430 431 NovoLog is recommended for use with the Disetronic H-TRON[®] series. MiniMed 500 432 series, or other pumps recommended by your doctor. 433 434 1. Inspect your insulin as you would for an injection. The insulin should be clear and 435 colorless and without particles. The tamper-resistant cap should be in place to be 436 removed by you. If the cap had been removed before your first use of the vial or if the 437 insulin is cloudy or colored, you should return the vial to the pharmacy. Do not use it. 438 2. Both the infusion site and your hands should be cleaned with soap and water or with 439 alcohol. The infusion site should be dry before you insert the catheter-needle and 440 tubing. Do not use skin that is reddened, itchy, bumpy or thickened as an infusion site 441 because the onset and duration of NovoLog action may not be the same as that in 442 normal skin. 443 3. Fill the reservoir-syringe with 2 days worth of NovoLog plus about 25 extra units to 444

445 prime the pump and fill up the dead space of the infusion tubing.

4. Remove air bubbles from the reservoir according to the pump manufacturers' 446 instructions. 447 5. Attach the infusion set to the reservoir. Make sure the connection is tight. Prime the 448 infusion set until you see a drop of insulin coming out of the infusion needle-catheter. 449 Flick the tubing to remove air bubbles. Follow the pump manufacturers' instructions 450 for additional priming. 451 6. Prime the needle-catheter and insert the infusion set into the skin according to the 452 pump manufacturer. 453 7. Program the pump for mealtime NovoLog boluses and NovoLog basal insulin 454 infusion according to instructions from your doctor and the manufacturer of your 455 pump equipment. 456 8. Change the infusion site, the insulin reservoir, the tubing, the catheter-needle, and the 457 insulin every 48 hours or less, even if you have not used all of the insulin. This will 458 help ensure that NovoLog and the pump works well. (See "What is the most 459 important information I should know about NovoLog?") 460 9. Change the infusion site, the insulin reservoir, the tubing, the catheter-needle, and the 461 insulin if you experience a pump alarm, catheter blockage, hyperglycemia, or if your 462 pump insulin has been exposed to heat greater than 98.6°F (37°C). (See "What is the 463 most important information I should know about NovoLog?") Hyperglycemia 464 identified with glucose monitoring may be the first indication of a problem with the 465 pump, infusion set, or NovoLog. Hyperglycemia in the absence of an alarm still 466 467 requires you to investigate because pump alarms are designed to detect back-pressure and occlusion. The alarms may not detect all the changes to NovoLog that could 468 result in hyperglycemia. You may need to resume subcutaneous insulin injections if 469 470 the cause of the problem cannot be promptly identified or fixed. (See "Hyperglycemia" under "What are the possible side effects of NovoLog?") 471 Remember that long stretches of tubing increase the risk for kinking and expose the 472 insulin in the tubing to more variations in temperature. 473 474 These instructions give you specific information for use of NovoLog in external 475 subcutaneous infusion pumps, but are not a substitute for pump education. 476 477 How should I mix insulins? 478 479 NovoLog should be mixed only when syringe injections are used. NovoLog can be 480 mixed with NPH human insulin immediately before use. The NovoLog should be drawn 481 into the syringe before the NPH. Mixing with other insulins has not been studied. 482 NovoLog should not be mixed with Lantus[®] (insulin glargine [rDNA origin] 483 injection). Mixed insulins should NEVER be used in a pump or for intravenous 484 infusion. 485 486 1. Add together the doses of NPH and NovoLog. The total dose will determine the final 487 volume in the syringe after drawing up both insulins into the syringe. 488 2. Roll the NPH vial between your hands until the liquid is equally cloudy throughout. 489 3. Draw into the syringe the same amount of air as the NPH dose. Inject this air into the 490 NPH vial and then remove the needle without withdrawing or touching any of the 491

NPH insulin. (Transferring NPH to the NovoLog vial will contaminate the NovoLog 492 vial and may change how quickly it works.) 493 4. Draw into the syringe the same amount of air as the NovoLog dose. Inject this air into 494 the NovoLog vial. With the needle in place, turn the vial upside-down and withdraw 495 the correct dose of NovoLog. The tip of the needle must be in the NovoLog to get the 496 full dose and not an air dose. 497 5. Insert the needle into the NPH vial. Turn the NPH vial upside down with the syringe-498 needle still in it. Withdraw the correct dose of NPH. 499 6. Inject immediately to reduce changes in how quickly the insulin works. 500 501 502 Helpful information for people with diabetes is published by the American Diabetes 503 Association, 1660 Duke Street, Alexandria, VA 22314 504 505 For information contact: 506 507 Novo Nordisk Pharmaceuticals Inc., 100 College Road West 508 509 Princeton, New Jersey 08540 510 1-800-727-6500 www.novonordisk-us.com 511 512 513 Manufactured by Novo Nordisk A/S 514 2880 Bagsvaerd, Denmark 515 516 517 License under U.S. Patent No. 5,618,913 and Des. 347,894 518 NovoLog[®], PenFill[®], NovoPen[®], Innovo®, NovoFine[®], and Lente[®] are trademarks of 519 520 Novo Nordisk A/S. Lantus[®] is a trademark of Aventis Pharmaceuticals Inc. 521 H-TRON[™] is a trademark of Disetronic Medical Systems, Inc. 522 InDuoTM is a trademark of LifeScan, Inc., a Johnson & Johnson company. 523 524 525 Date of Issue: XX xx, 2004 526 527 8-XXXX-XX-XXX-X 528 529 Printed in Denmark 530 531 532